AbCellera Biologics (ABCL) Short Interest Ratio & Short Volume

Short interest is the volume of AbCellera Biologics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 18,430,000 shares of ABCL short. 8.31% of AbCellera Biologics' shares are currently sold short. Learn More on AbCellera Biologics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABCL shares currently have a short interest ratio of 6.0. Learn More on AbCellera Biologics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of AbCellera Biologics: Group One Trading LLC, Citadel Advisors LLC, Concourse Financial Group Securities Inc., and National Bank of Canada FI. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.31% of AbCellera Biologics' floating shares are currently sold short.

AbCellera Biologics saw a increase in short interest in January. As of January 31st, there was short interest totaling 18,430,000 shares, an increase of 6.8% from the previous total of 17,260,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

AbCellera Biologics currently has issued a total of 295,370,000 shares. Some of AbCellera Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. AbCellera Biologics currently has a public float of 221,910,000 shares.

8.31% of AbCellera Biologics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to AbCellera Biologics: Avidity Biosciences, Inc. (12.53%), ADMA Biologics, Inc. (5.58%), Arcellx, Inc. (18.01%), Akero Therapeutics, Inc. (5.20%), Rhythm Pharmaceuticals, Inc. (8.35%), Scholar Rock Holding Co. (16.66%), Immunovant, Inc. (19.21%), Apellis Pharmaceuticals, Inc. (13.71%), Viking Therapeutics, Inc. (21.47%), ACADIA Pharmaceuticals Inc. (9.75%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

Short selling ABCL is an investing strategy that aims to generate trading profit from AbCellera Biologics as its price is falling. ABCL shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for AbCellera Biologics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABCL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABCL, twice per month. The most recent reporting period available is January, 31 2025.